2-tert-Butyl-1,4-benzoquinone

2-tert-Butyl-1,4-benzoquinone (12.5-500 μg/mL; 17 h, MIC assay; 12.5-50 μg/mL; 24 h, growth curve assay) has a minimum inhibitory concentration of 125 μg/mL against Chromobacterium violaceum ATCC12472, and sub-MIC concentrations (12.5, 25, 50 μg/mL) do not significantly inhibit bacterial growth over 24 h^[1].
2-tert-Butyl-1,4-benzoquinone (12.5-50 μg/mL; 17 h) dose-dependently inhibits C10‒HSL production in Chromobacterium violaceum ATCC12472, reducing production by 65% at a concentration of 50 μg/mL after 17 h incubation^[1].
2-tert-Butyl-1,4-benzoquinone (12.5-50 μg/mL; 17 h) dose-dependently inhibits the production of violacein, chitinase, and hemolysin in Chromobacterium violaceum ATCC12472, with maximum inhibitions of 70.6%, 72%, and 70.5%, respectively, at a concentration of 50 μg/mL after 17 h incubation^[1].
2-tert-Butyl-1,4-benzoquinone (12.5-50 μg/mL; 48 h) dose-dependently inhibits the swimming motility of Chromobacterium violaceum ATCC12472, reducing motility by 88.45% at a concentration of 50 μg/mL after 48 h incubation^[1].
2-tert-Butyl-1,4-benzoquinone (50 μg/mL; 24 h, combined with 0.2 μg/mL ciprofloxacin) synergistically inhibits biofilm formation by 73.27% and reduces cell survival in Chromobacterium violaceum ATCC12472 biofilms after 24 h incubation^[1].
2-tert-Butyl-1,4-benzoquinone (50 μM; 0.5, 1, 3, 6, 9 h) activates Nrf2 (peaking at 3 h) and induces HO-1 in HepG2 cells, and these effects are enhanced by GSH depletion and diminished by thiol enhancement, consistent with GSH-dependent S-transarylation of TBQ-modified Keap1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.